BioCentury

2:19 AM GMT, Feb 3, 2009
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Top Story

Tarceva-Avastin combo meets endpoint

Genentech (NYSE:DNA) said a DSMB recommended ending the Phase IIIb ATLAS trial for first-line treatment of non-small cell

Read the full 189 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.